source
- Neurocrine’s rare-disease drug approved but later linked to deaths and serious side effectsNeurocrine Biosciences received regulatory approval for a rare‑disease therapy after a small clinical trial showed modest efficacy and side effects that were considered manageable. The decision was…
- Neurocrine's Prader-Willi drug Vykat XR linked to multiple deaths and serious side effectsA group of physicians and experts in Prader-Willi syndrome warned clinicians about safety concerns with Vykat XR, a drug approved by the FDA in March 2025 to reduce the intense hunger in patients w…